Asset Acquisition, Assets Acquired

No definition available.

Name:	gild_AssetAcquisitionAssetsAcquired
Namespace Prefix:	gild_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Asset Acquisition, Liabilities Assumed

+ References

No definition available.

+ Details

Name:	gild_AssetAcquisitionLiabilitiesAssumed
Namespace Prefix:	gild_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Asset Acquisition, Liabilities Assumed, Change Of Control Payment

+ References

No definition available.

+ Details

Name:	gild_AssetAcquisitionLiabilitiesAssumedChangeOfControlPayment
Namespace Prefix:	gild_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Equity Method Investment, Additional Interest Acquired, Shares

+ References

No definition available.

+ Details

Name:	gild_EquityMethodInvestmentAdditionalInterestAcquiredShares
Namespace Prefix:	gild_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Equity Method Investment, Additional Investment

+ References

No definition available.

+ Details

Name:	gild_EquityMethodInvestmentAdditionalInvestment
Namespace Prefix:	gild_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Equity Method Investment, Option Fee

+ References

No definition available.

+ Details

Name:	gild_EquityMethodInvestmentOptionFee
Namespace Prefix:	gild_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Equity Method Investment, Ownership Interest, Shares

+ References

No definition available.

+ Details

Name:	gild_EquityMethodInvestmentOwnershipInterestShares
Namespace Prefix:	gild_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Number Of Designees On Board Of Directors

+ References

No definition available.

+ Details

Name:	gild_NumberOfDesigneesOnBoardOfDirectors
Namespace Prefix:	gild_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Payments For Asset Acquisitions

+ References

No definition available.

+ Details

Name:	gild_PaymentsForAssetAcquisitions
Namespace Prefix:	gild_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Payments To Extinguish Future Royalty Obligation

+ References

No definition available.

+ Details

Name:	gild_PaymentsToExtinguishFutureRoyaltyObligation
Namespace Prefix:	gild_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Potential Future Milestone Payments, Maximum

+ References

No definition available.

+ Details

Name:	gild_PotentialFutureMilestonePaymentsMaximum
Namespace Prefix:	gild_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (h)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Name:	us-gaap_AllocatedShareBasedCompensationExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 55
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479908/805-50-55-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480060/805-50-25-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 30
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480027/805-50-30-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 30
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480027/805-50-30-2

+ Details

Name:	us-gaap_AssetAcquisitionConsiderationTransferred
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

+ Details

Name:	us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Amount of writeoff for research and development asset acquired in transaction other than business combination or from joint venture formation or both.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482665/350-30-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 985
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481283/985-20-50-2

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482916/730-10-50-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_ArcusBiosciencesIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=gild_ArcusBiosciencesIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementLocationAxis=us-gaap_NonoperatingIncomeExpenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AssetAcquisitionAxis=gild_CymaBayMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=gild_JanssenPharmaceuticaNVMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AssetAcquisitionAxis=gild_XinTheraIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AssetAcquisitionAxis=gild_TmunityTherapeuticsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=gild_TmunityAndUniversityOfPennsylvaniaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

ACQUISITIONS, COLLABORATIONS AND OTHER ARRANGEMENTS (Details) shares in Millions, $ in Millions		1 Months Ended					3 Months Ended				6 Months Ended		12 Months Ended
	Feb. 22, 2023 USD ($)	Jul. 31, 2024 USD ($)	Mar. 31, 2024 USD ($)	Jan. 31, 2024 USD ($) designee shares	Oct. 31, 2023 USD ($)	May 31, 2023 USD ($)	Jun. 30, 2024 USD ($)	Mar. 31, 2024 USD ($)	Jun. 30, 2023 USD ($)	Mar. 31, 2023 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Dec. 31, 2023 USD ($)
Business Combination, Separately Recognized Transactions [Line Items]
Acquired in-process research and development expenses							$ 38		$ 236		$ 4,169	$ 717
Arcus
Business Combination, Separately Recognized Transactions [Line Items]
Ownership interest, shares (in shares) \| shares				30.1
Ownership percentage				33.00%
Arcus
Business Combination, Separately Recognized Transactions [Line Items]
Additional interest acquired, shares (in shares) \| shares				15.2
Additional equity investment				$ 320
Option fee				$ 100
Number of designees \| designee				3
Arcus \| Prepaid and other current assets
Business Combination, Separately Recognized Transactions [Line Items]
Additional equity investment				$ 233
Arcus \| Other (Income) Expense
Business Combination, Separately Recognized Transactions [Line Items]
Additional equity investment				$ 87
CymaBay
Business Combination, Separately Recognized Transactions [Line Items]
Total consideration transferred			$ 3,900
Acquired in-process research and development expenses								$ 3,900			$ 3,900
Asset acquisition, assets acquired			263					263
Asset acquisition, liabilities assumed			$ 228					228
Change of control payment							$ 101
Share-based compensation expense								133
CymaBay \| Research and development expenses
Business Combination, Separately Recognized Transactions [Line Items]
Share-based compensation expense								67
CymaBay \| Selling, general and administrative expenses
Business Combination, Separately Recognized Transactions [Line Items]
Share-based compensation expense								$ 67
CymaBay \| Janssen Pharmaceutica NV \| Subsequent Event
Business Combination, Separately Recognized Transactions [Line Items]
Payment to extinguish a future royalty obligation		$ 320
XinThera, Inc
Business Combination, Separately Recognized Transactions [Line Items]
Acquired in-process research and development expenses					$ 50				$ 170
Cash consideration						$ 200
Maximum potential future milestone payments						$ 760
Tmunity Therapeutics
Business Combination, Separately Recognized Transactions [Line Items]
Acquired in-process research and development expenses										$ 244
Cash consideration	$ 300
Tmunity Therapeutics \| Tmunity And University Of Pennsylvania
Business Combination, Separately Recognized Transactions [Line Items]
Acquired in-process research and development expenses													$ 25
Maximum potential future milestone payments										$ 1,000